Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21201454 | 0.76 | IDO1 (0.37) | — | |
| SCHEMBL21687452 | 0.75 | TRPV4 (0.35) | TTR | |
| SCHEMBL18245444 | 0.75 | TTR (0.31) | TTR | |
| SCHEMBL2490883 | 0.71 | MAPK1 (0.38) | — | |
| SCHEMBL11385650 | 0.70 | BACE1 (0.35) | — | |
| SCHEMBL7792827 | 0.70 | TTR (0.36) | ERN1TTRPKM | |
| SCHEMBL97070 | 0.69 | — | — | |
| SCHEMBL3145381 | 0.67 | TTR (0.56) | ERN1TTR | |
| SCHEMBL616435 | 0.67 | — | — | |
| SCHEMBL180319 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| EP-0656209-A2 | Melatonin derivatives for use in treating desynchronization disorders | ELI LILLY AND COMPANY (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0655243-A2 | Melatonin derivatives for use in treating sleep disorders | ELI LILLY AND COMPANY (US) | 1995-05-31 | — | — | EP | disclosed |
| EP-0543659-B1 | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma | LILLY CO ELI (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0543659-A1 | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma | ELI LILLY AND COMPANY (US) | 1993-05-26 | — | — | EP | disclosed |
| US-5196435-A | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0281242-B1 | BETA-ALKYLMELATONINS | ELI LILLY AND COMPANY (US) | 1992-08-12 | — | — | EP | disclosed |
| US-4997845-A | β-alkylmelatonins as ovulation inhibitors | ELI LILLY AND COMPANY (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0281242-A1 | Beta-alkylmelatonins | ELI LILLY AND COMPANY (US) | 1988-09-07 | — | — | EP | disclosed |
| CN-88100478-A | alkyl melatonin | — | 1988-08-17 | — | — | CN | disclosed |
| US-4087444-A | Amides as ovulation inhibitors | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | ERN1 1875/4885TTR 4044/4885PKM 2836/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | ERN1 1153/4885TTR 4593/4885PKM 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.